FG-M131 / FutureGen Biopharmaceutical - LARVOL DELTA

A Phase I/II Study of FG-M131 in TRBC1+ Relapsed/Refractory Peripheral T-Cell Lymphoma (clinicaltrials.gov) - P1/2 | N=110 | Not yet recruiting | Sponsor: FutureGen Biopharmaceutical (Beijing) Co., Ltd

New P1/2 trial • Cutaneous T-cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma